{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:14:47Z","timestamp":1790792087829,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Deutschland GmbH"},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["No 648131"],"award-info":[{"award-number":["No 648131"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["No 847770"],"award-info":[{"award-number":["No 847770"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"German Center for Cardiovascular Research","doi-asserted-by":"publisher","award":["81Z1710103"],"award-info":[{"award-number":["81Z1710103"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"German Center for Cardiovascular Research","doi-asserted-by":"publisher","award":["81Z0710114"],"award-info":[{"award-number":["81Z0710114"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry of Research and Education","award":["BMBF 01ZX1408A"],"award-info":[{"award-number":["BMBF 01ZX1408A"]}]},{"name":"German Ministry of Research and Education","award":["ERACoSysMed3 (031L0239)"],"award-info":[{"award-number":["ERACoSysMed3 (031L0239)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We investigated the relation of HF in the ETNA-AF-Europe registry, a prospective, multicentre, observational study with an overall 4-year follow-up of edoxaban-treated AF patients. We report 2-year follow-up for ischaemic stroke\/transient ischaemic attack (TIA)\/systemic embolic events (SEE), major bleeding, and mortality. Of the 13 133 patients, 1854 (14.1%) had HF. Left ventricular ejection fraction was available for 82.4% of HF patients and was &amp;lt;40% in 671 (43.9%) and \u226540% in 857 (56.1%). Patients with HF were older, more often men, and had more comorbidities. Annualized event rates (AnERs) of any stroke\/SEE were 0.86%\/year and 0.67%\/year in patients with and without HF. Compared with patients without HF, those with HF also had higher AnERs for major bleeding (1.73%\/year vs. 0.86%\/year) and all-cause death (8.30%\/year vs. 3.17%\/year). Multivariate Cox proportional models confirmed HF as a significant predictor of major bleeding [hazard ratio (HR) 1.65, 95% confidence interval (CI): 1.20\u20132.26] and all-cause death [HF with LVEF &amp;lt;40% (HR 2.42, 95% CI: 1.95\u20133.00) and HF with LVEF \u226540% (HR 1.80, 95% CI: 1.45\u20132.23)] but not of ischaemic stroke\/TIA\/SEE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anticoagulated patients with HF at baseline featured higher rates of major bleeding and all-cause death, requiring optimized management and novel preventive strategies. NOAC treatment was similarly effective in reducing risk of ischaemic events in patients with or without concomitant HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euad280","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:23:04Z","timestamp":1694719384000},"source":"Crossref","is-referenced-by-count":20,"title":["Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7170-9509","authenticated-orcid":false,"given":"Renate B","family":"Schnabel","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Clinic Hamburg-Eppendorf, University Heart and Vascular Centre Hamburg-Eppendorf , Buildung O50, Martinistrasse 52, 20246 Hamburg , Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), partner site Hamburg\/Kiel\/Luebeck , Potsdamer Str, 5810785 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7287","authenticated-orcid":false,"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova , Genova , Italy"},{"name":"Cardiac, Thoracic and Vascular Department, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1635","authenticated-orcid":false,"given":"Jolanta M","family":"Siller-Matula","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-3809","authenticated-orcid":false,"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna , 40138 Bologna , Italy"},{"name":"Unit of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna , 40138 Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gwechenberger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-3178","authenticated-orcid":false,"given":"Ladislav","family":"Pecen","sequence":"additional","affiliation":[{"name":"Czech Academy of Science, Institute of Computer Sciences , Prague, Czech Republic"},{"name":"Department of Immunochemistry Diagnostics, University Hospital Pilsen , Pilsen , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius Constantin","family":"Manu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Souza","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[{"name":"Cardiology Division, Pisa University Hospital , Pisa , Italy"},{"name":"Fondazione Villa Serena per la Ricerca , Pescara , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham , UK"},{"name":"Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Centre Hamburg Eppendorf , Hamburg , Germany"},{"name":"German Center for Cardiovascular Sciences (DZHK), partner site Hamburg\/Kiel\/L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"2023092912250245400_euad280-B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/IJGM.S188524","article-title":"Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia","volume":"12","author":"Mashat","year":"2019","journal-title":"Int J Gen Med"},{"key":"2023092912250245400_euad280-B2","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"2023092912250245400_euad280-B3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCEP.112.970749","article-title":"Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry","volume":"5","author":"Chiang","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2023092912250245400_euad280-B4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023092912250245400_euad280-B5","doi-asserted-by":"crossref","first-page":"e015218","DOI":"10.1161\/JAHA.119.015218","article-title":"Comparison of cardiovascular risk factors in European population cohorts for predicting atrial fibrillation and heart failure, their subsequent onset, and death","volume":"9","author":"Schrage","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023092912250245400_euad280-B6","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"2023092912250245400_euad280-B7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurjhf\/hfp085","article-title":"A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure","volume":"11","author":"Mamas","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2023092912250245400_euad280-B8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/164_2016_126","article-title":"Anticoagulation therapy and NOACs in heart failure","volume":"243","author":"Thomas","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2023092912250245400_euad280-B9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10741-018-9693-0","article-title":"Anticoagulation in atrial fibrillation with heart failure","volume":"23","author":"Zhao","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2023092912250245400_euad280-B10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ejhf.343","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials","volume":"17","author":"Xiong","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2023092912250245400_euad280-B11","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023092912250245400_euad280-B12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2459\/JCM.0000000000000737","article-title":"Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study","volume":"20","author":"De Caterina","year":"2019","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2023092912250245400_euad280-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2023092912250245400_euad280-B14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2023092912250245400_euad280-B15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2023092912250245400_euad280-B16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12877-015-0051-y","article-title":"Perceived frailty and measured frailty among adults undergoing hemodialysis: a cross-sectional analysis","volume":"15","author":"Salter","year":"2015","journal-title":"BMC Geriatr"},{"key":"2023092912250245400_euad280-B17","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ehf2.12857","article-title":"Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF","volume":"7","author":"Dubner","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2023092912250245400_euad280-B18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jchf.2016.07.012","article-title":"Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis","volume":"4","author":"Savarese","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2023092912250245400_euad280-B19","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.jacc.2017.09.027","article-title":"Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction","volume":"70","author":"Mogensen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023092912250245400_euad280-B20","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023092912250245400_euad280-B21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2023092912250245400_euad280-B22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2023092912250245400_euad280-B23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2023092912250245400_euad280-B24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","article-title":"Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF","volume":"6","author":"van Diepen","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2023092912250245400_euad280-B25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ejhf.595","article-title":"Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48","volume":"18","author":"Magnani","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2023092912250245400_euad280-B26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.112.000143","article-title":"Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"6","author":"McMurray","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2023092912250245400_euad280-B27","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.1946","article-title":"What should the C (\u2018congestive heart failure\u2019) represent in the CHA(2) DS(2)-VASc score?","volume":"22","author":"Mulder","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023092912250245400_euad280-B28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2018.04.093","article-title":"Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: the PREFER in AF - HF substudy","volume":"265","author":"Siller-Matula","year":"2018","journal-title":"Int J Cardiol"},{"key":"2023092912250245400_euad280-B29","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2009-02-207928","article-title":"Outcomes and predictors of very stable INR control during chronic anticoagulation therapy","volume":"114","author":"Witt","year":"2009","journal-title":"Blood"},{"key":"2023092912250245400_euad280-B30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2020.08.021","article-title":"Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: a network meta-analysis","volume":"196","author":"Jin","year":"2020","journal-title":"Thromb Res"},{"key":"2023092912250245400_euad280-B31","doi-asserted-by":"crossref","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2023092912250245400_euad280-B32","doi-asserted-by":"crossref","first-page":"101652","DOI":"10.1016\/j.arr.2022.101652","article-title":"Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients","volume":"79","author":"Proietti","year":"2022","journal-title":"Ageing Res Rev"},{"key":"2023092912250245400_euad280-B33","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/ejhf.1832","article-title":"The prevalence and importance of frailty in heart failure with reduced ejection fraction\u2014an analysis of PARADIGM-HF and ATMOSPHERE","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023092912250245400_euad280-B34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/europace\/euac123","article-title":"EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"25","author":"Savelieva","year":"2023","journal-title":"Europace"},{"key":"2023092912250245400_euad280-B35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/europace\/euac004","article-title":"Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis","volume":"24","author":"Diemberger","year":"2022","journal-title":"Europace"},{"key":"2023092912250245400_euad280-B36","doi-asserted-by":"crossref","first-page":"afac192","DOI":"10.1093\/ageing\/afac192","article-title":"Epidemiology and impact of frailty in patients with atrial fibrillation in Europe","volume":"51","author":"Proietti","year":"2022","journal-title":"Age Ageing"},{"key":"2023092912250245400_euad280-B37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/europace\/euac022","article-title":"Impact of oral anticoagulation on the association between frailty and clinical outcomes in people with atrial fibrillation: nationwide primary care records on treatment analysis","volume":"24","author":"Wilkinson","year":"2022","journal-title":"Europace"},{"key":"2023092912250245400_euad280-B38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cjca.2021.09.021","article-title":"The introduction of direct oral anticoagulants has not resolved treatment gaps for frail patients with nonvalvular atrial fibrillation","volume":"38","author":"Orlandi","year":"2022","journal-title":"Can J Cardiol"},{"key":"2023092912250245400_euad280-B39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.123.066485","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","author":"Joosten","year":"2023.","journal-title":"Circulation"},{"key":"2023092912250245400_euad280-B40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"key":"2023092912250245400_euad280-B41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ejhf.2729","article-title":"Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in &gt;400 000 participants in the Get With The Guidelines-Heart Failure Registry","volume":"25","author":"Patel","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2023092912250245400_euad280-B42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/europace\/euac082","article-title":"Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial","volume":"24","author":"Patel","year":"2022","journal-title":"Europace"},{"key":"2023092912250245400_euad280-B43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.121.056323","article-title":"Early rhythm control therapy in patients with atrial fibrillation and heart failure","volume":"144","author":"Rillig","year":"2021","journal-title":"Circulation"},{"key":"2023092912250245400_euad280-B44","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euad280\/51606061\/euad280.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/9\/euad280\/51797737\/euad280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/9\/euad280\/51797737\/euad280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:03:14Z","timestamp":1695978194000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad280\/7274739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad280","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,8,2]]},"article-number":"euad280"}}